ES2425308T3 - Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2) - Google Patents

Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2) Download PDF

Info

Publication number
ES2425308T3
ES2425308T3 ES09730771T ES09730771T ES2425308T3 ES 2425308 T3 ES2425308 T3 ES 2425308T3 ES 09730771 T ES09730771 T ES 09730771T ES 09730771 T ES09730771 T ES 09730771T ES 2425308 T3 ES2425308 T3 ES 2425308T3
Authority
ES
Spain
Prior art keywords
ace2
tumor
cancer
activity
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09730771T
Other languages
English (en)
Spanish (es)
Inventor
Evelyne Janzek-Hawlat
Hans Loibner
Manfred Schuster
Bernhard Peball
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeiron Biologics AG
Original Assignee
Apeiron Biologics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeiron Biologics AG filed Critical Apeiron Biologics AG
Application granted granted Critical
Publication of ES2425308T3 publication Critical patent/ES2425308T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES09730771T 2008-04-09 2009-04-07 Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2) Active ES2425308T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0056608A AT506632A1 (de) 2008-04-09 2008-04-09 Behandlung von tumorerkrankungen
AT5662008 2008-04-09
PCT/AT2009/000136 WO2009124330A2 (de) 2008-04-09 2009-04-07 Behandlung von tumorerkrankungen

Publications (1)

Publication Number Publication Date
ES2425308T3 true ES2425308T3 (es) 2013-10-14

Family

ID=41130316

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09730771T Active ES2425308T3 (es) 2008-04-09 2009-04-07 Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2)

Country Status (12)

Country Link
US (1) US8946162B2 (OSRAM)
EP (2) EP2274005B1 (OSRAM)
JP (1) JP5650639B2 (OSRAM)
AT (1) AT506632A1 (OSRAM)
AU (1) AU2009235931B2 (OSRAM)
CA (1) CA2720616C (OSRAM)
DK (1) DK2274005T3 (OSRAM)
ES (1) ES2425308T3 (OSRAM)
NZ (1) NZ588435A (OSRAM)
PL (1) PL2274005T3 (OSRAM)
PT (1) PT2274005E (OSRAM)
WO (1) WO2009124330A2 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
CN104395750B (zh) * 2012-06-06 2017-06-30 阿托奎特诊断有限公司 测量血液样品中蛋白水解级联的肽降解产物的方法
US8557958B1 (en) 2012-06-18 2013-10-15 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of diabetes
US8633158B1 (en) 2012-10-02 2014-01-21 Tarix Pharmaceuticals Ltd. Angiotensin in treating brain conditions
CA2897251C (en) * 2013-01-14 2022-07-12 Apeiron Biologics Ag Modified ace2 polypeptides
PL3079684T3 (pl) * 2013-12-11 2020-06-01 Alterras Therapeutics Gmbh Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
US9333233B2 (en) 2014-02-25 2016-05-10 Tarix Pharmaceuticals Ltd. Methods and compositions for the delayed treatment of stroke
US20200188473A1 (en) * 2017-05-02 2020-06-18 Beth Israel Deaconess Medical Center, Inc. Combination therapy for cancer
EP3717077A1 (en) * 2017-11-29 2020-10-07 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
US20230181759A1 (en) * 2020-04-01 2023-06-15 Washington University Compositions for treatment of viral respiratory infections and methods of use thereof
CN112626099A (zh) * 2020-09-29 2021-04-09 清华大学 使用原核细胞发酵表达血管紧张素转化酶2的方法
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2023102156A1 (en) 2021-12-03 2023-06-08 Wisconsin Alumni Research Foundation Mutant ace2 proteins and methods of using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194556B1 (en) 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
WO2003072059A2 (en) * 2002-02-27 2003-09-04 Wake Forest University Angiotensin-(1-7) and angiotensin-(1-7) agonists for inhibition of cancer cell growth
EP2047867B1 (en) * 2002-06-19 2013-05-22 Apeiron Biologics AG ACE2 activation for treatment of heart, lung and kidney disease and hypertension
EP1374907A3 (en) 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid

Also Published As

Publication number Publication date
AU2009235931A1 (en) 2009-10-15
AU2009235931B2 (en) 2015-07-23
US20110033524A1 (en) 2011-02-10
EP2274005B1 (de) 2013-05-29
AT506632A1 (de) 2009-10-15
WO2009124330A3 (de) 2009-12-10
JP5650639B2 (ja) 2015-01-07
CA2720616C (en) 2016-08-09
CA2720616A1 (en) 2009-10-15
WO2009124330A2 (de) 2009-10-15
NZ588435A (en) 2012-10-26
US8946162B2 (en) 2015-02-03
PT2274005E (pt) 2013-08-27
DK2274005T3 (da) 2013-08-19
PL2274005T3 (pl) 2013-12-31
EP2274005A2 (de) 2011-01-19
JP2011516501A (ja) 2011-05-26
EP2644203A1 (de) 2013-10-02

Similar Documents

Publication Publication Date Title
ES2425308T3 (es) Tratamiento de enfermedades tumorales mediante enzima convertidora de angiotensina 2 (ACE2)
TWI480048B (zh) 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途
ES2624196T3 (es) Inhibidores polipéptidicos de HSP27 quinasa y usos de los mismos
ES2664086T3 (es) Liberación extendida de neurregulina para mejorar la función cardíaca
EP3072519A1 (en) Peptide having angiogenesis inhibitory activity and composition containing same
Nagaraja et al. Role of human and mouse HspB1 in metastasis
ES2796973T3 (es) Métodos y composiciones para reducir el crecimiento, la migración y la invasividad de células madre de cáncer cerebral y mejorar la supervivencia de pacientes con tumores cerebrales
CN112543809A (zh) 包含C/EBPα saRNA的组合疗法
CN114585384A (zh) 使用C/EBPα saRNA的组合物和方法
ES2728675T3 (es) Variantes de semaforina 3C, composiciones que comprenden dichas variantes y métodos de utilización de las mismas
US8822421B2 (en) E2F as a target of hormone refractory prostate cancer
JP2016216476A (ja) 伸長α鎖を有するフィブリノーゲンが濃縮されたフィブリノーゲン調製物
ES2330918T3 (es) Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
ES2481645T3 (es) Tratamiento de fibrosis y enfermedades hepáticas
CA3177876A1 (en) Anti-cancer proteins
WO2022076932A1 (en) Compositions and methods of treating a pi3k mediated disease
CN110215511A (zh) 微肽asrps在治疗癌症中的应用
US20250049888A1 (en) Use of the negr1 protein and biologically active fragments thereof in the therapeutic treatment of alk-related diseases
US10870690B2 (en) Protein therapeutant and method for treating cancer
KR101848106B1 (ko) Gkn2를 유효성분으로 포함하는 항암 보조제
JP2008517045A (ja) 癌の治療法
EA048362B1 (ru) Противораковые белки
JPWO2023118291A5 (OSRAM)
RU2009142817A (ru) Ферментативная противоопухолевая терапия
WO2015196312A1 (es) Moléculas inhibidoras del receptor lox-1 y su incidencia directa en el control de la progresión tumoral en diversos tipos de cáncer humanos